MTOR and renal cell carcinoma: Similarly, pathway enrichment results revealed a marked involvement in the JAK–STAT, interferon, and mTOR signaling pathways, suggesting that MTAP/CDKN2AMUT may activate the anti-tumor immune response in the TME of RCC (Figure 5B).